When patients are told they need surgery for a cervical disc problem — a herniated disc, a pinched nerve, or early signs of spinal cord compression — two procedures are typically on the table: anterior cervical discectomy and fusion (ACDF) and cervical disc replacement (arthroplasty). Both decompress the nerve or spinal cord through the same anterior approach. The key difference is what happens afterward: ACDF permanently immobilizes the treated level, while disc replacement preserves motion.
For much of the history of cervical spine surgery, ACDF was the default. Disc replacement was introduced as an alternative in the early 2000s and, after extensive clinical trials, received FDA approval. The question patients and surgeons reasonably asked was: does preserving motion actually matter? Does it translate into better outcomes over time? More than a decade of prospective randomized clinical trial data now gives us a meaningful answer.
What the trials measured
Multiple FDA investigational device exemption (IDE) trials compared cervical disc replacement to ACDF in patients with one or two level cervical disc disease causing radiculopathy or myelopathy. These were prospective, randomized, controlled trials — the highest level of clinical evidence — with follow-up extended to 7, 10, and in some cases beyond 10 years. Primary outcome measures included neck disability index, pain scores for neck and arm, neurological success, overall success, and the need for secondary surgical procedures.
What the data shows
Neurological outcomes are equivalent. Both procedures achieve similar rates of arm pain relief, neurological recovery from radiculopathy, and neurological stabilization in myelopathy. This was expected and confirmed consistently across trials. Patients should not choose one procedure over the other based on an expectation of better nerve decompression — the decompression is identical.
Disc replacement patients have lower reoperation rates at adjacent levels. This is the most clinically significant finding of the long-term data. Multiple trials have demonstrated that patients treated with disc replacement have significantly lower rates of requiring a second surgery at adjacent levels compared to patients treated with ACDF. At 10-year follow-up in several trials, the absolute difference in adjacent level reoperation rates has ranged from roughly 5 to 10 percentage points — meaningful numbers when considering a surgical decision.
The mechanism is straightforward: ACDF eliminates motion at the fused level, transferring increased mechanical stress to the adjacent discs and facet joints. Over years to decades, this accelerated stress contributes to degeneration at adjacent levels. Disc replacement preserves motion at the treated level, distributing forces more normally.
Disc replacement patients maintain functional range of motion. Long-term imaging in disc replacement patients confirms that the treated level retains functional motion in the majority of cases.
Safety profiles are comparable. The trials have not demonstrated a higher rate of serious complications with disc replacement compared to ACDF.
What the data does not show
It would be inaccurate to conclude that disc replacement is universally superior to ACDF. The trials enrolled carefully selected patients who met specific candidacy criteria — preserved lordosis, no significant facet arthritis, no instability, 1–2 level disease. For patients with cervical kyphosis, significant facet joint disease, instability, multilevel spondylosis, or OPLL, ACDF remains the appropriate procedure and disc replacement data does not apply.
The difference in adjacent level reoperation at 10 years is meaningful but not dramatic. The absolute numbers mean that the majority of ACDF patients do not require adjacent level reoperation. The data supports offering disc replacement to candidates — it does not mean ACDF patients are destined for revision surgery.
What this means for patients
For patients who meet the candidacy criteria for cervical disc replacement — 1–2 level disc disease, preserved lordosis, no significant facet arthritis or instability — the 10-year data supports disc replacement as the preferred option when the goal is minimizing the likelihood of future surgery at adjacent levels while achieving equivalent neurological outcomes.
For patients who do not meet these criteria, ACDF remains an excellent procedure with a long track record of success. The choice between the two should be based on individual anatomy and pathology, not on general preference for one technique over another.
Dr. Sardar completed a dedicated fellowship in artificial disc replacement at the Texas Back Institute and is equally expert in both procedures. His approach is to evaluate every patient for disc replacement candidacy and recommend genuinely what is best for each patient’s anatomy, diagnosis, and goals.
This post is for educational purposes only and does not constitute individualized medical advice. The clinical trial data referenced reflects the published literature on FDA IDE trials for cervical arthroplasty. Please consult a qualified spine specialist to discuss your specific situation.